Neuro Pathophysiology PPT Flashcards

1
Q

DSM-5 Criteria to diagnose dementia:
* Significant _____ decline from the ______ level
of performance in one or more cognitive domains
* Interferes with _____
* Does not occur exclusively in the context of a
delirium
* Not better explained by any other ______ or _________ condition

A

DSM-5 Criteria to diagnose dementia:
* Significant cognitive decline from the baseline level
of performance in one or more cognitive domains
* Interferes with the activities of daily living
* Does not occur exclusively in the context of a
delirium
* Not better explained by any other medical or
psychiatric condition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

DSM-5 Criteria for delirium:
* Disturbance in _____ & _______
* Develops ______ and tends to ______
in severity.
* At least one additional disturbance in
cognition
* Not better explained by _______ ________
* Do not occur in the context of a
severely reduced level of arousal or
coma
* Evidence of an ______ _________

A

DSM-5 Criteria for delirium:
* Disturbance in attention & awareness
* Develops acutely and tends to fluctuate
in severity.
* At least one additional disturbance in
cognition
* Not better explained by preexisting
dementia.
* Do not occur in the context of a
severely reduced level of arousal or
coma
* Evidence of an underlying organic
cause or causes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pathophysiology of Major Neurocognitive Disorder:

Accumulation of native _____ in the brain
(except vascular)

A

Pathophysiology of Major Neurocognitive Disorder:

Accumulation of native proteins in the brain
(except vascular)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Vascular dementia ~____% of all dementia cases
* Incidence increases with ___
* Doubles every _____ years
* Risk factors (4):

A

Vascular dementia ~15% of all dementia cases
* Incidence increases with age
* Doubles every 5.3 years
* Risk factors - hypercholesteremia, diabetes
mellitus, hypertension, and smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Lewy body dementia ___% of dementia cases

A

Lewy body dementia: ~5% of dementia cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Parkinson disease dementia ___% of cases of
dementia

A
  • Parkinson disease dementia 10% of cases of
    dementia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Frontotemporal dementia ~___% of dementia
cases in patients older than ____ years of age

A

Frontotemporal dementia ~25% of dementia
cases in patients older than 65 years of age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dementia-type diseases:
Cause _______ damage to various areas of your brain, causing _______ in
several areas of the brain to die

A

Dementia-type diseases:
Cause progressive damage to various areas of your brain, causing neurons in
several areas of the brain to die

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Dementia-type diseases: (5)

A
  • Alzheimer’s disease
  • Frontotemporal dementia
  • Chronic traumatic encephalopathy (CTE)
  • Lewy body dementia
  • Limbic predominant age-related TDP-43 encephalopathy
    (LATE)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Alzheimer’s
Disease:

Premature aging of the brain Alzheimer disease is the most common cause of
dementia, ___ to ___% of all
cases of dementia.

Number is projected to double every ____ years and will increase to reach ____ million by 2050.

Characterized by a _______ decline in ______ and
_________ in personal daily activities.

A

Alzheimer’s
Disease:

Premature aging of the brain
Alzheimer disease is the most common cause of
dementia - 70 to 80% of all
cases of dementia.

Number is projected to double every 5 years and will
increase to reach 152 million by 2050.

Characterized by:

progressive decline in thinking and
independence in personal daily activities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

The National Institute on Aging—
Alzheimer’s Association
(updated the 1984 NINCDS-ADRDA criteria for
higher specificity and sensitivity)

  • Positive lesions (due to __________),
    characterized by the
    _________ of __________ tangles,
    _________ plaques, dystrophic neurites, neuropil threads, and other deposits found in the brains
  • Negative lesions (due to _____), that are characterized by large _______ due to a neural, neuropil, and synaptic loss
A
  • Positive lesions (due to accumulation),
    characterized by the
    accumulation of neurofibrillary tangles,
    amyloid plaques, dystrophic neurites, neuropil threads, and other deposits found in the brains
  • Negative lesions (due to losses), that are characterized by large atrophy due to a neural, neuropil, and synaptic loss
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Alzheimer’s Disease Pathophysiology:

  • Widespread _____ of the cortex
  • Neuritic plaques composed of extracellular
    ______ ______ _______ deposition
  • Neurofibrillary tangles composed of
    ________ ____ proteins
  • Common to see signs of vascular ______
    damage and _________ ______
A

Alzheimer’s Disease Pathophysiology:

  • Widespread atrophy of the cortex
  • Neuritic plaques composed of extracellular
    amyloid beta protein deposition
  • Neurofibrillary tangles composed of
    hyperphosphorylated tau proteins
  • Common to see signs of vascular ischemic
    damage and hippocampal sclerosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Alzheimer’s Disease:

Genetics:
1. All known mutations increase production of ____-______ proteins
2. ________ ____ patients – 3 copies of gene for
_______ precursor protein
3. Abnormality of gene controlling ___________
(cholesterol transporter) – accelerated deposition
of amyloid
4. Generation of anti-_______ ___________ in
Alzheimer disease appear to attenuate disease
process

A

Alzheimer’s Disease:

Genetics:
1. All known mutations increase production of beta-amyloid proteins
2. Trisomy 21 patients – 3 copies of gene for amyloid precursor protein
3. Abnormality of gene controlling apolipoprotein (cholesterol transporter) – accelerated deposition of amyloid
4. Generation of anti-amyloid antibodies in Alzheimer disease appear to attenuate disease process

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Risk factors for Alzheimer’s (6):

A

Several risk factors
* increasing age
* genetic factors
* head injuries
* vascular diseases
* Infections
* environmental factors -
heavy metals, trace
metals, and others
Cerebrovascular disease caused by hypertension &
atherosclerosis may play role in dementia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

_______, _________, & ________ increase risk
for developing dementia & progression of Alzheimer’s

A

Hypertension, diabetes, & hyperlipidemia increase risk for developing dementia & progression of Alzheimer’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

T/F

Lifestyle factors do not directly affect Alzheimer’s
disease pathology but can still contribute to a negative
outcome in individuals with Alzheimer’s disease.

A

False

Lifestyle factors do not directly affect Alzheimer’s
disease pathology but can still contribute to a positive
outcome in individuals with Alzheimer’s disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Promising pharmacological treatments for Alzheimer’s are poised at
advanced stages of clinical trials and include (3)

A

anti-amyloid β
anti-tau
anti-inflammatory strategies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Clinical Phases of Alzheimer’s:

  1. Pre-clinical or the pre-symptomatic stage:
  • mild _______ loss
  • early pathological changes in ______ and ________
  • no functional impairment in _____
  • absence of clinical signs and symptoms
A

Clinical Phases of Alzheimer’s:

  1. Pre-clinical or the pre-symptomatic stage:
  • mild memory loss
  • early pathological changes in cortex and hippocampus
  • no functional impairment in ADLs
  • absence of clinical signs and symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Clinical Phases of Alzheimer’s:

  1. Mild or early stage
    * _______ start to appear in patients
    * trouble in the daily life
    * loss of ________ and _______
    * disorientation of place and time
    * change in _____
    * development of ________
A

Clinical Phases of Alzheimer’s:

  1. Mild or early stage
    * symptoms start to appear in patients
    * trouble in the daily life
    * loss of concentration and memory
    * disorientation of place and time
    * change in mood
    * development of depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Clinical Phases of Alzheimer’s:

  1. Moderate stage
    * disease spreads to _______ ______ areas
    * increased memory loss
    * trouble _________
    * loss of ______ control
    * difficulty in ______, ______, and ______
A

Clinical Phases of Alzheimer’s:

  1. Moderate stage
    * disease spreads to cerebral cortex areas
    * increased memory loss
    * trouble recognizing family and friends
    * loss of impulse control
    * difficulty in reading, writing, and speaking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Clinical Phases of Alzheimer’s:

  1. Severe AD or late-stage
    * spread of the disease to the entire _____ area
    * severe accumulation of _______ ______ and __________ tangles
    * progressive functional and cognitive impairment - cannot recognize their family at all
    * become ______
    * difficulties in ______ and ______
    * eventually leading to ____
A

Clinical Phases of Alzheimer’s:

  1. Severe AD or late-stage
    * spread of the disease to the entire cortex area
    * severe accumulation of neuritic plaques and neurofibrillary tangles
    * progressive functional and cognitive impairment - cannot recognize their family at all
    * become bedridden
    * difficulties in swallowing and urination
    * eventually leading to death
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Frontotemporal Dementia
Neurodegenerative disorder is a spectrum of clinical syndromes
characterized by ______ degeneration involving the ______ and
_____ ________ lobes of the brain

A

Frontotemporal Dementia
Neurodegenerative disorder is a spectrum of clinical syndromes
characterized by neuronal degeneration involving the frontal and
anterior temporal lobes of the brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Frontotemporal Dementia
Neurodegenerative disorde :

Clinical manifestations (5):

Etiology (2):

A

Clinical manifestations (5):
* behavior changes
* dietary changes
* loss of empathy
* Apathy
* Executive function

Etiology (2):
* Genetic
* Head trauma and thyroid disease linked with the development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Chronic Traumatic Encephalopathy
(CTE):

Neurodegenerative disease exhibiting a distinct pattern of neuropathological changes associated with _________ leading to increased risk of long-term memory and cognition issue.

Causes lesions at traumatic stress points leading to (3):

A

Chronic Traumatic Encephalopathy
(CTE):

Neurodegenerative disease exhibiting a distinct pattern of neuropathological changes associated with repetitive head trauma leading to increased risk of long-term memory and cognition issue.

Causes lesions at traumatic stress points leading to (3):
* axonal injury
* micro-hemorrhages
* subsequent loss of blood brain barrier integrity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Dementia Anesthesia Considerations:

Assessment of cognitive ability, capacity for decision making, & risk factors for POD
* Preoperative neuropsychiatric assessment –
establish baseline
Mini-Cog Assessment:
* Highly sensitive & specific for dementia
* Unbiased by variances in education & language
Criteria for Decision-making Capacity
1. Understanding treatment options
2. Appreciating & acknowledging medical condition & outcomes
3. Exhibiting reasoning & engaging in rational discussion of surgical treatment options
4. Clearly choosing a preferred treatment option

CNS changes result in increased sensitivity to anesthetic
agent
Changes in mood, memory, & motor function
* Increased risk for POD or further decrease in cognitive
disfunction
* Increased sensitivity d/t receptor downregulation
* Blood-brain barrier more permeable
* Decreased nerve conduction velocity

Pharmacological Interactions
Comprehensive medication list – multitude of anesthetic
implications
CNS changes result in increased sensitivity to anesthetic
agent

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Frontotemporal Dementia
Neurodegenerative disorder:

Treatment (2 categories):

A

Frontotemporal Dementia
Neurodegenerative disorder:

Treatment (2 categories):

Non-pharmacologic:
social support services, physical therapy
& occupational therapy, speech therapy, cognitive behavior therapy, rehabilitation services, and caregivers’ education

Pharmacologic:
* Acetylcholinesterase inhibitors and N-methyl-D-aspartate inhibitors
* Selective serotonin reuptake inhibitors (SSRIs)
* Antipsychotics
* Dopaminergic antagonists
* Salsalate (tau acetylation inhibitor) and gosuraneb (anti-tau monoclonal antibodies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Frontotemporal Dementia
Neurodegenerative disorder

Pharmacologic Treatment:

A

Frontotemporal Dementia
Neurodegenerative disorder

Pharmacologic:
* Acetylcholinesterase inhibitors and N-methyl-D-aspartate inhibitors
* Selective serotonin reuptake inhibitors (SSRIs)
* Antipsychotics
* Dopaminergic antagonists
* Salsalate (tau acetylation inhibitor) and gosuraneb (anti-tau monoclonal antibodies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Chronic Traumatic Encephalopathy
(CTE):

Trigger an ________ cascade and a deposition of:

phosphorylated tau (p-tau) protein amyloid-beta (Aβ)
TDP-43
neurofibrillary triangles
neutrophil neurites
astrocytic tangles
neuronal loss and cerebral atrophy with white matter changes.

Symptoms (7):

A

Chronic Traumatic Encephalopathy
(CTE):

Trigger an inflammatory cascade and a deposition of:

*phosphorylated tau (p-tau) protein *amyloid-beta (Aβ)
*TDP-43
*neurofibrillary triangles
*neutrophil neurites
*astrocytic tangles
*neuronal loss and cerebral atrophy with white matter changes.

Symptoms (7):
* changes in behavior
* cognition and motor symptoms
* impulsivity, paranoia, rage behaviors,
* headaches
* memory deficits, impaired attention
* dysphagia, dysarthria,
* coordination problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q
  • Most prevalent demyelinating disorders
  • Combinations of inflammation, demyelination, and axonal
    damage in the central nervous system
  • Loss of myelin covering the axons is followed by formation of
    demyelinated plaques.
  • Immune mediated inflammatory disease
A

Multiple Sclerosis (MS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Common demyelinating diseases that
affect your central nervous system
(brain and spinal cord) include (6):

A
  • Multiple sclerosis (MS)
  • Neuromyelitis optica spectrum disorder (NMOSD)
  • Transverse myelitis (TM)
  • Acute disseminated
    encephalomyelitis (ADEM)
  • Progressive multifocal
    leukoencephalopathy (PML).
  • Central pontine myelinolysis
    (osmotic demyelination
    syndrome).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Multiple Sclerosis (MS) attacks what anatomical structures (3):

A
  • myelin
  • oligodendrocytes (myelin producing cells)
  • underlying nerve fibers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Multiple
Sclerosis (MS) Symptoms (11):

A

a) Fatigue
b) Tingling
c) Numbness
d) Muscle weakness
e) Ataxia
f) Vertigo
g) Tremor
h) Spasticity
i) Bowel & bladder disfunction
j) Pain
k) Heat intolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Multiple Sclerosis:

Contribute to ________ & _______
* Affects young adults between ages ___-___ years of age
* ______ affected two times more than ___
* Significant disability results in __ - __ years
* Characterized by periods of ______ & _______

A

Multiple Sclerosis:

Contribute to demyelination & neurodegeneration
* Affects young adults between ages 20-40 years of age
* Females affected two times more than males
* Significant disability in 20 -25 years
* Characterized by periods of relapse & remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Multiple
Sclerosis (MS) Diagnosis (3):

A

a) MRI
b) Elevated IgG in the cerebrospinal fluid
c) Decreased conduction velocity on evoke potential studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Treatment of Multiple
Sclerosis (MS):

__________ agents directed toward reducing
formation of new lesions & decreasing incidence of relapse

A

Treatment of Multiple
Sclerosis (MS):

Immunomodulatory agents directed toward reducing
formation of new lesions & decreasing incidence of relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Multiple Sclerosis (MS) Risk Factors (6):

A

Risk Factors:
a) female sex
b) exposure to Epstein-Barr or varicella zoster viruses
c) diabetes mellitus type 1
d) inflammatory bowel disease
e) low vitamin D levels
f) smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Multiple Sclerosis Anesthesia Considerations:

  • Consider the impact of surgical ______ on the natural ______ of the disease
  • Possible signs & symptoms of MS will be ______ _______
  • infection and fever: increased body temperature results in complete _____ of _____ in __________ nerves
A

Multiple Sclerosis Anesthesia Considerations:

  • Consider the impact of surgical stress on the natural progression of the disease
  • Possible signs & symptoms of MS will be exacerbated postoperatively
  • infection and fever: increased body temperature results in complete block of conduction in demyelinated nerves
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Multiple Sclerosis Anesthesia Considerations:

T/F

There is NO evidence to support the use of one inhaled or injected anesthetic drug over another

A

Multiple Sclerosis Anesthesia Considerations:

TRUE

There is NO evidence to support the use of one inhaled or injected anesthetic drug over another

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Multiple Sclerosis Anesthesia Considerations:

Muscle relaxants

  • Avoid use of _______ in patients with _____ weakness

use of _______ can result in exaggerated ________ release and should be avoided

A

Multiple Sclerosis Anesthesia Considerations:

Avoid use of succinylcholine in patients with motor weakness

use of succinylcholine can result in exaggerated potassium release and should be avoided

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Multiple Sclerosis Anesthesia Considerations:

Muscle Relaxants

  • Avoid use of succinylcholine in patients with ______ weakness
  • _______ responses to the paralyzing effects of _________ muscle relaxants
  • coexisting skeletal muscle ______ and decreased skeletal muscle _____
  • _______ to the effects of nondepolarizing muscle relaxants has been observed
  • reflects the proliferation of extrajunctional ________ receptors characteristic of ______ motor neuron lesions
A

Multiple Sclerosis Anesthesia Considerations:

Muscle Relaxants

  • Avoid use of succinylcholine in patients with motor weakness
  • Prolonged responses to the paralyzing effects of nondepolarizing muscle relaxants
  • coexisting skeletal muscle weakness and decreased skeletal muscle mass
  • Resistance to the effects of nondepolarizing muscle relaxants has been observed
  • reflects the proliferation of extrajunctional cholinergic receptors characteristic of upper motor neuron lesions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Multiple Sclerosis Anesthesia Considerations:

  • Corticosteroid supplementation – consideration in patients on long-term corticosteroids
A

???

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Multiple Sclerosis Anesthesia Considerations:

Regional anesthetic techniques - changing and unpredictable neurologic presentation during the perioperative period must be appreciated

  • hypothesized that intrathecal administration of _____ anesthetics promoted demyelination in the spinal cord
  • ______ regions of the spinal cord may be _____ susceptible to the ______ effects of ______ anesthetics
  • _____ and _____ analgesia & anesthesia have been used safely
A

Multiple Sclerosis Anesthesia Considerations:

Regional anesthetic techniques - changing and unpredictable neurologic presentation during the perioperative period must be appreciated

  • hypothesized that intrathecal administration of local anesthetics promoted demyelination in the spinal cord
  • Demyelinated regions of the spinal cord may be more susceptible to the neurotoxic effects of local anesthetics
  • epidural and spinal analgesia & anesthesia have been used safely
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

GBS Progression:

________ response triggers an _________ response to peripheral nerves & spinal root

Symptoms progress over several days to reach peak at ___ to ___ weeks

  • max loss of function ___ hours
  • 4 weeks ______ _______ to limit of symptoms
  • Recovery protracted for months to years – depend on extent of ______ injury
A

GBS Progression:

Autoimmune response triggers an autoimmune response to peripheral nerves & spinal root
Symptoms progress over several days to reach peak at 2 to 4 weeks
* max loss of function 72 hours
* 4 weeks most progressed to limit of symptoms
* Recovery protracted for months to years – depend on extent of nerve injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Most common variant of GBS - Acute Inflammatory demyelinating polyneuropathy (AIDP)

Manifest as:
* _______ _______ muscle weakness that progressively leads to severe flaccid _____ &
respiratory _____

  • Sensory & motor features depend on _____
  • _____ of patients have history of ____ or _____ infection
  • Severe limb weakness
  • Related to ______ antibody response against GMI & GDI a gangliosides
    MFS
  • Anti-GQ1b antibodies
A

Most common variant of GBS - Acute Inflammatory demyelinating polyneuropathy (AIDP)
Manifest as:

  • symmetric ascending muscle weakness that progressively leads to severe flaccid paralysis &
    respiratory failure
  • Sensory & motor features depend on subtype
  • Half of patients have history of bacterial or viral infection
  • Severe limb weakness
  • Related to autoimmune antibody response against GMI & GDI a gangliosides
    MFS
  • Anti-GQ1b antibodies
  • Symptoms affect cranial nerves resulting in clinical triad: ophthalmoplegia, ataxia, & areflexia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Common demyelinating diseases that
affect your peripheral nervous system
include (3):

A
  • Guillain-Barré
    syndrome (GBS)
  • Charcot-Marie-Tooth
    disease (CMT)
  • Chronic inflammatory
    demyelinating
    polyneuropathy (CIDP)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Guillain-Barré
syndrome (GBS):

Occurring at a rate of 1-2 cases/100,000 persons per
year worldwide
* Increases with ____
* More prevalent in ___

A

Guillain-Barré
syndrome (GBS)

Occurring at a rate of 1-2 cases/100,000 persons per
year worldwide
* Increases with age
* More prevalent in men

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Most common variant of GBS

A

Acute Inflammatory demyelinating polyneuropathy (AIDP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

GBS Symptoms:

affect ______ nerves resulting in clinical triad:

A

GBS Symptoms:

affect cranial nerves resulting in clinical triad:

*ophthalmoplegia
*ataxia
*areflexia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q
  • Progressive dementia combined with choreoathetosis
  • Marked atrophy of the caudate nucleus - lesser degree putamen & globus pallidus
  • Abnormal movements caused by the loss of most of the cell bodies:
  • GABA-secreting neurons in the caudate nucleus & putamen
  • Acetylcholine-secreting neurons in many parts of the brain
  • Loss of inhibition allows spontaneous outbursts of globus pallidus & substantia nigra activity that cause the
    distortional movements
    Treatment
  • Supportive - directed at decreasing the choreiform movement
  • Haloperidol and other butyrophenones - control the chorea and emotional lability
  • Drugs that interfere with the neurotransmitter effects of dopamine
  • antagonizing dopamine (risperidone, olanzapine)
  • depleting dopamine stores (tetrabenazine, deutetrabenazine)
    Anesthesia Considerations
  • Preoperative sedation - butyrophenones such as droperidol or haloperidol - controlling choreiform movements
  • Increased likelihood of pulmonary aspiration
  • Acceptable anesthesia techniques include
  • Nitrous oxide & inhalational anesthetics
  • Propofol & succinylcholine
  • Spinal anesthesia
A

?????

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Stroke Risk factors (8):

A
  • Hypertension
  • Diabetes
  • Smoking
  • Atherosclerosis
    Stroke-related disorders of the cerebrovascular system
  • atherosclerotic disease of the carotid artery
  • cerebral aneurysm
  • arteriovenous malformation
  • moyamoya disease.
54
Q

Blood supply to the brain is via two pairs of vessels:

A
  • internal carotid arteries
  • vertebral arteries
55
Q

Vessels join on the inferior surface of the brain to form the _____ of _____ - during ideal circumstances, provides collateral circulation to multiple areas of the brain.

A

Vessels join on the inferior surface of the brain to form the Circle of Willis - during ideal circumstances, provides collateral circulation to multiple areas of the brain.

56
Q

Carotid arteries vessels comprise the ______ circulation (5):

A

Carotid arteries vessels comprise the anterior circulation (5):

  • Frontal
  • Parietal
  • lateral temporal lobes
  • basal ganglia
  • most of the internal capsule
57
Q

Vertebral arteries each give rise to a ______-______ cerebellar artery before converging at the level of the _____ to form the
_______ artery

Areas (5):

A

Vertebral arteries each give rise to a posterior-inferior cerebellar artery before converging at the level of the pons to form the
basilar artery

Areas (5):

  • Brainstem
  • occipital lobes
  • Cerebellum
  • medial portions of the temporal lobes
  • most of the thalamus
58
Q

Ischemic Stroke

Prognosis depends on the _____ _______ from the onset of symptoms to thrombolytic intervention if thrombosis is the cause
of the symptoms.

A

Ischemic Stroke

Prognosis depends on the time elapsed from the onset of symptoms to thrombolytic intervention if thrombosis is the cause
of the symptoms.

59
Q

An ischemic stroke is the result of an _______ of a vessel that supplies a region of brain resulting in cellular ______ and subsequent
cellular ________.

A

An ischemic stroke is the result of an occlusion of a vessel that supplies a region of brain resulting in cellular ischemia and subsequent
cellular death.

60
Q

Parkinson’s Disease:

Nonmotor Features (4):

A

Parkinson’s Disease:

Nonmotor Features:

  1. sleep disturbances
  2. depression and anxiety
  3. autonomic dysfunction
  4. cognitive impairment in advanced stages
61
Q

Parkinson’s Disease – paralysis agitans:

Widespread degeneration of the portion of the _______ ______ that
sends _________ secreting nerve fibers to the _____ ______ and ________.

A

Parkinson’s Disease – paralysis agitans

Widespread degeneration of the portion of the substantia nigra that
sends dopamine secreting nerve fibers to the caudate nucleus and
putamen.

62
Q

Parkinson’s Disease:

_______ is presumed to inhibit the rate of firing of the neurons that control the _________ motor system.

A

Parkinson’s Disease:

Dopamine is presumed to inhibit the rate of firing of the neurons that control the extrapyramidal motor system.

63
Q

Parkinson’s Disease:

  1. Loss of ______ fibers normally present in
    the ____ _______
  2. Result regional _____ concentrations are
    ______
  3. Depletion of ______ results in diminished
    ______ of these neurons and unopposed
    stimulation by __________
A

Parkinson’s Disease:

  1. Loss of dopaminergic fibers normally present in
    the basal ganglia
  2. Result regional dopamine concentrations are
    depleted
  3. Depletion of dopamine results in diminished
    inhibition of these neurons and unopposed
    stimulation by acetylcholine
64
Q

Parkinson’s Disease – paralysis agitans:

Symptoms:

  • ______ of much of the _______ of the body
  • Involuntary _____ at a fixed rate of 3 to 6 cycles/sec of the involved areas (resting)
  • Serious difficulty in initiating movement, called –
    ______
  • Postural instability caused by impaired _____
    reflexes, leading to poor balance and falls
  • Other motor symptoms, including ______
    (impaired ability to swallow), _____ disorders,
    ____ disturbances, and ______
A

Parkinson’s Disease – paralysis agitans:

Symptoms:

  • Rigidity of much of the musculature of the body
  • Involuntary tremor at a fixed rate of 3 to 6
    cycles/sec of the involved areas (resting)
  • Serious difficulty in initiating movement, called –
    akinesia
  • Postural instability caused by impaired postural
    reflexes, leading to poor balance and falls
  • Other motor symptoms, including dysphagia
    (impaired ability to swallow), speech disorders,
    gait disturbances, and fatigue
65
Q

Parkinson’s Disease:

Rigidity: destruction of the _______ neurons in the _____ ______ allow the caudate nucleus and putamen to
become overly active and possibly cause continuous output of _______ signals to the ________ motor control system

A

Parkinson’s Disease:

Rigidity: destruction of the dopaminergic neurons in the substantia nigra allow the caudate nucleus and putamen to
become overly active and possibly cause continuous output of
excitatory signals to the corticospinal motor control system

66
Q

Parkinson’s Disease:

Involuntary Tremor:

feedback circuits ______ because of high
feedback gains after loss of their inhibition (occurs during all ______ hours)

A

Parkinson’s Disease:

Involuntary Tremor:

feedback circuits oscillate because of high feedback gains after loss of their inhibition (occurs during all waking hours)

67
Q

Parkinson’s Disease:

Akinesia - dopamine secretion in the _____ system (nucleus accumbens) is decreased, along with its decrease in the basal ganglia - this decrease might reduce the _____ for motor
activity so greatly that akinesia results

A

Parkinson’s Disease:

Akinesia - dopamine secretion in the limbic system (nucleus accumbens) is decreased, along with its decrease in the basal ganglia - this decrease might reduce the psychic drive for motor
activity so greatly that akinesia results

68
Q

Parkinson’s Treatment:

Goal of therapy: increase concentrations of ______ in the basal ganglia or
decrease the neuronal effects of ____________

A

Parkinson’s Treatment:

Goal of therapy: increase concentrations of dopamine in the basal ganglia or
decrease the neuronal effects of acetylcholine

69
Q

Parkinson’s Treatments:

  1. Levodopa
  • Dopamine precursor
  • converted into dopamine (brain) - restores the normal balance between inhibition and excitation in the caudate nucleus and putamen
  • ameliorates many of the motor disturbances, especially the rigidity and akinesia
  • little beneficial effect on nonmotor symptoms
    Monoamine oxidase inhibitors
  • monoamine oxidase is responsible for destruction of most of the dopamine after it has been secreted
  • any dopamine that is released remains in the basal ganglial tissues for a longer time
  • helps to slow destruction of the dopamine-secreting neurons in the substantia nigra
  1. Transplanted Fetal Dopamine Cells:
  • Transplantation into the caudate nuclei and putamen has been used with some short-term success to treat Parkinson’s disease
  1. Surgical treatment:
    * Ablative treatments – pallidotomy & thalamotomy
  • Implantations deep brain stimulating device
  • Transcranial magnetic resonance-guided focus ultrasound
A
70
Q

Huntington’s Disease:

___________ ________ hereditary disease – trinucleotide repeats in the gene for Huntington’s

A

Huntington’s Disease:

Autosomal dominant hereditary disease – trinucleotide repeats in the gene for Huntington’s

71
Q

________ is characterized by sudden neurologic deficits
resulting from ischemia (____% of cases) or hemorrhage
(____% of cases).

A

Stroke is characterized by sudden neurologic deficits
resulting from ischemia (88% of cases) or hemorrhage
(12% of cases).

72
Q

The anterior and posterior circulations communicate via the _______
communicating artery, and the left and right ______ cerebral arteries
communicate via the _______ communicating artery.

A

The anterior and posterior circulations communicate via the posterior communicating artery, and the left and right anterior cerebral arteries
communicate via the anterior communicating artery.
Occlusion of specific arteries distal to the Circle of Willis results in
predictable clinical neurologic deficits.

73
Q

T/F

Occlusion of specific arteries distal to the Circle of Willis results in predictable clinical neurologic deficits.

A

TRUE

74
Q

A transient ischemic attack (TIA) is a _____ vascular-related focal neurologic deficit that resolves
within ___ hours without intervention.

*~ ____-______ of patients who suffer a TIA will suffer
a stroke

A

A transient ischemic attack (TIA) is a sudden vascular-related focal neurologic deficit that resolves
within 24 hours without intervention.

*~ 1/3 of patients who suffer a TIA will suffer
a stroke

75
Q

Risk of acute ischemic stroke (6):

A
  • Systemic hypertension - most significant risk factor
  • Cigarette smoking
  • Hyperlipidemia
  • Diabetes mellitus
  • Excessive alcohol consumption
  • Increased serum homocysteine
    concentrations
76
Q

Stroke Anesthesia Considerations:

Pre-operative considerations:
* _____ is important – event to intervention is crucial (rapid)
* Depressed _____
* Ability to protect
_____
* Claustrophobic
* Anxiety
* Full stomach/ GERD
* Pulmonary disorders
* _______ status
* Impact choice of
_______ medications &
________ goals

A

Stroke Anesthesia Considerations:

Pre-operative considerations
* Time is important – event to intervention is crucial (rapid)
* Depressed LOC
* Ability to protect
airway
* Claustrophobic
* Anxiety
* Full stomach/ GERD
* Pulmonary disorders
*Neurological
status
* Impact choice of
vasoactive medications &
hemodynamic goals

77
Q

Stroke Anesthesia Considerations:

Maintain PaO2:
* Above ____ mmHG
* SaO2 above ___%

Maintain BP
Before revascularization:
* Systolic -____ to ____ mmHg
* Diastolic – below ___ mmHg

After
revascularization
* Systolic ____ – ____ mmHg

Fluids
* ______
* ______
* Avoid fluids containing ____

Glucose Level
* Between ____ -_____
mg/dL
* Below ___ mg/dL –
treat w/dextrose solution

Heparin
* ACT of _____ – ____seconds

  • _______ reversal (give
    slowly)
A

Stroke Anesthesia Considerations:

Maintain PaO2
* Above 60 mmHG
* SaO2 above 92%

Maintain BP
Before revascularization
* Systolic 140-180 mmHg
* Diastolic – below 105 mmHg

After
revascularization
* Systolic -120 –140 mmHg

Fluids:
* Isotonic
* Euvolemia
* Avoid fluids
containing glucose

Glucose Level:
* Between 140 -180 mg/dL
* Below 60 mg/dL – treat w/dextrose solution

Heparin:
* ACT of 250 – 300
seconds

  • Protamine
    reversal (give
    slowly)
78
Q

Intraparenchymal Hemorrhage:

A

bleeding that occurs within the brain’s functional tissue, or parenchyma

79
Q

Extradural Hemorrhage:

Involve arteries that supply the _____ _____ located
between the ____ _____ & ______ of the cranial
bones – accumulation of blood in ______ space
Compress the brain & decrease perfusion

A

Extradural Hemorrhage:

Involve arteries that supply the dura mater located
between the dura mater & periosteum of the cranial
bones – accumulation of blood in epidural space
Compress the brain & decrease perfusion

80
Q

Subdural Hemorrhage:

Blood accumulation between ____ _____ & ______ layer - Rupture of bridging veins that run in the _____ space

A

Subdural Hemorrhage:

Blood accumulation between dura mater & arachnoid layer - Rupture of bridging veins that run in the subdural space

81
Q

Cerebral aneurysm are abnormal, localized ______ of the intracranial arteries

A

Cerebral aneurysm are abnormal, localized dilations of the intracranial arteries
Classifications
* Berry
* Mycotic
* Traumatic
* Fusiform
* Neoplastic
* Atherosclerotic

82
Q

An estimated __ million people in the US have an
unruptured cerebral aneurysm.

Ruptured aneurysms are fatal in approximately ___%
cases

Giant aneurysm – greater than ___ inch in diameter

A

An estimated 6 million people in the US have an
unruptured cerebral aneurysm.

Ruptured aneurysms are fatal in approximately 40%
cases

Giant aneurysm – greater than 1 inch in diameter

83
Q

Subarachnoid hemorrhage

Signs & Symptoms (7):

  • Intense headache
  • Transient loss of consciousness
  • Nausea & vomiting
  • Photophobia
  • Fever
  • Meningism
  • Focal neurological deficits
A

Subarachnoid hemorrhage

Signs & Symptoms (7):

  • Intense headache
  • Transient loss of consciousness
  • Nausea & vomiting
  • Photophobia
  • Fever
  • Meningism
  • Focal neurological deficits
84
Q

Vasospasm – delayed & sustained ________ cerebral arteries

  • Leading cause morbidity & mortality with SAH after
    aneurysm rupture
  • Decrease in _____ ______ & ___
  • Neurological deterioration arising from impaired ______ perfusion, ______, and secondary _______ of the brain peaks between the ____ and ____ day.
A

Vasospasm – delayed & sustained contraction cerebral arteries

  • Leading cause morbidity & mortality with SAH after
    aneurysm rupture
  • Decrease in blood flow & CPP
  • Neurological deterioration arising from impaired cerebral perfusion, ischemia, and secondary infarction of the brain
    peaks between the 3rd and 14th day.
85
Q

Cerebral Vasospasm Treatment:

  • Oral nimodipine & hypertensive therapy
  • Ballon angioplasty & intraarterial vasodilator infusion
  • Papaverine - Off-label use calcium channel antagonist

Prevent & Treat Ischemic Neurological Deficits:

  • Hypervolemia – colloids & crystalloids
  • Hypertension – fluid loading & vasopressors
  • Hemodilution – 27% - 30%

Maintain systolic BP
* 120 – 150 mmHg before clipping

  • Max 160 -180 mmHg systolic & MAP 110 mmHg after clipping

Maintain HR
80 – 120 b/min

Management of intracranial aneurysm rupture (Box 31.8
Nagelhout: page 737)

A
86
Q

Intracranial
Space:

  • Total volume of contents -1300 to 1500ml
  • Components
  • Brain (80% to 90% of volume)
  • Blood
  • Intracellular water
  • Cerebral Spinal Fluid (CSF)
  • Brain is not compressible, any increase in total intracranial volume produces an
    accompany increase in ICP
  • Any expansion of one component
    necessitates a reduction of another component if ICP is to remain constant.

CSF is absorbed
* microscopic arachnoid villa
* macroscopic arachnoid granulations
* dura matter
* bordering venous sinusoids
* sinuses
* blood-brain barrier

A
87
Q

Cerebrospinal Fluid
System:

Origin of secretions

  • Choroid plexus in 4 ventricles
  • Ependymal surfaces
    Rate – 30ml/hr
  • Entire CSF volume replaced every 3 to 4 hours

Absorption
* Arachnoid villi act as valves

A
88
Q

Monro-Kellie Doctrine:

The cranium (or neurocranium) describes the part of the skull
encasing the brain, made up of 8 bones (frontal, ethmoid, sphenoid,
occipital, paired parietals, and paired temporal). As the cranium is
made from solid bone*, its structure is fixed and therefore the volume
contained within cannot be changed.

The intracranial pressure (ICP) is the pressure within the cranium
of the skull. Due to the fixed nature of the cranium, an increase in
volume of any one of the intracranial components will also cause an
increase in pressure.

Therefore, in the absence of pathology, an equilibrium between
these three components must be maintained to preserve a normal
intracranial pressure. If the volume of one of the components
within the cranium increases, the volume of a different component
must decrease to maintain this equilibrium and sustain a normal ICP.

A
89
Q

Intracranial:

Various meningeal barriers within the intracranial vault that functionally separate
the contents:

Falx cerebri (a reflection of dura mater that separates the two cerebral
hemispheres)

Tentorium cerebelli (a reflection of dura mater that lies rostral to the cerebellum and marks the border between the supratentorial and infratentorial spaces).

Intracranial Vault
If one of the other components increases in size or a new
component (with its own volume and own contribution to intracranial
pressure) is introduced into the cranial cavity, its volume may be small enough that the skull volume can accommodate and
compensatory mechanisms can be employed to maintain a normal
intracranial pressure.

The main compensatory mechanisms are increased drainage of blood or cerebrospinal fluid from the cranial cavity.

Once volume compensation has reached exhaustion, the
subsequent increasing ICP has a direct relationship with a reduction in cerebral perfusion and an increased risk of herniation.

A
90
Q

Subfalcine herniation -
herniation of cerebral
hemispheric contents
under the falx cerebri

Leads to compression of branches of the anterior
cerebral artery and is evident on radiographic imaging
as midline shift

Transtentorial herniation
- brainstem compression
occurs in a rostral to
caudal manner

altered consciousness, defects in gaze and afferent ocular reflexes, and, finally, hemodynamic and respiratory compromise followed by death

Uncal herniation - uncus
(i.e., the medial portion of
the temporal lobe)
herniate over the
tentorium cerebelli

  • ipsilateral oculomotor nerve dysfunction because the
    oculomotor nerve is compressed against the brainstem
  • pupillary dilatation, ptosis, and lateral deviation of the
    affected eye, which occurs before evidence of
    brainstem compression and death.
A
91
Q

Intracranial Pressure (ICP):

  • Supratentorial cerebral spinal fluid pressure
  • Normal ICP 5 to 15 mmHg
    (adults)
  • Intracranial hypertension:
    20 to 25 mmHg
  • Cerebral Spinal Fluid (CSF)
    produced at a constant rate of 500 to 600 ml/day
A
92
Q

Increased ICP Signs & Symptoms:

  • Papilledema
  • Unilateral or bilateral mydriasis
  • Headache – postural, worse in the morning, made worse by coughing
  • Nausea & Vomiting
  • Slurred speech
  • Disoriented & altered levels of consciousness
  • Flaccid hemiplegia or hemiparesis
  • Abduction or oculomotor palsy
  • Neck rigidity
  • Respiratory disturbances
  • Arterial hypertension, w/bradycardia
  • Appearance of Q wave, deep & inverted T-waves, prolonged OT intervals, & ST segment elevation
A
93
Q

Causes of Increased ICP (5):

A

*Aqueductal stenosis
*Benign intracranial hypertension
*Normal pressure hydrocephalus
*Intracranial Hemorrhage
*IIntracranial tumors

94
Q

Stenosis of major CSF flow channels:

  • impede CSF flow
  • lead to increased ICP

Common causes of obstructive hydrocephalus - congenital narrowing of the cerebral aqueduct that connects the third and fourth ventricles

  • Characterized by ICP higher than 20 mm Hg, normal CSF composition, normal sensorium,
    and absence of local intracranial lesions.
  • Obese women
  • Patients with various systemic diseases, including polycystic ovary syndrome, systemic lupus erythematosus, Addison disease, hypoparathyroidism, and hypervitaminosis A
  • Triad of dementia, gait changes, and urinary incontinence – develops over a period of
    weeks to months
  • Related to compensated but impaired CSF absorption from a previous insult
    (subarachnoid hemorrhage, meningitis, or head trauma)
  • Lumbar puncture usually reveals normal or low CSF pressure, yet CT or MRI will often demonstrate large ventricles
A
95
Q

Highly invasive (strict sterile technique required)

  • Allows drainage of CSF to lower ICP

Gold Standard – Intraventricular catheter
* CSF leak
* Systemic infection
* Prophylactic antibiotics nor routine catheter exchange do NOT decrease incidence of infection

  • Intraventricular hemorrhage
  • Craniotomy

Risk Factors
* Severe TBI
* Glasgow Coma Scale score less than 9 w/abnormal CT scan

  • Normal CT scan w/ two or more;
  • Age older than 40
  • Unilateral or bilateral motor posturing
  • Systolic blood pressure less than 90 mmHg
    Recommended
A
96
Q

Hydrocephalus: Excess water on the brain

  • Communicating Hydrocephalus
  • Caused by blockage of fluid flow in the subarachnoid spaces
    around the basal region of the brain or blockage of the
    arachnoid villa where fluid id
    absorbed
  • Non-communicating
    Hydrocephalus
  • Caused by a block in the
    aqueduct of Sylvius, resulting from atresia (closure) before birth in many babies or from
    blockage by a brain tumor at
    any age

Treatment usually involves placement of a silicone tube from one of the ventricles to the peritoneal cavity.

A
97
Q

Therapeutic Modalities:

Patent airway, Adequate ventilation, & Controlled ventilation

Surgical Decompression
* Hematoma, contusion, tumor, hygroma, hydrocephalus,
pneumocephalus

Hyperventilation
* Hypocapnia – reduced ICP reflex vasoconstriction

  • Vasoconstriction
  • Lower PaCO2 Respiratory alkalosis vasoconstriction
  • CBF decreases by 4% per 1 mmHg decrease in PaCO2
  • Not used 1st 24 hours in TBI patients
  • Caution ischemia secondary to insufficient CBF (goal PaCO2 ~30 –
    35 mmHg)

CSF Drainage

  • Total volume 150 ml
  • Secreted ependymal cells of choroid plexus – rate 30ml/hr
  • Entire CSF volume replaced every 3 to 4 hours
  • Cycled in 10-minute intervals
  • Chronic – ventriculoperitoneal shunts
A
98
Q

Hypothermia

  • Management intractable intracranial hypertension
  • Trauma or hemorrhage – bladder temp 35 C to 36 C for 48 hours
  • Decrease CMRO2 by 7% for each degree centigrade decrease in core temp
  • Pharmacologic
  • Diuretics
    1. Loop diuretics – general diuresis - furosemide, bumetanide, ethacrynic acid
  1. Osmotic diuretics – decrease water content of brain – mannitol
  2. 0.25 – 1 g/kg
  3. Transient vasodilation – increase CBF – increase ICP
  4. Begin 30 minutes, maximum effect 1 to 2 hours, & last up to 6 hours
  5. Hypertonic saline – ICP reduction decrease water content (intact BBB) – 3% to
    23.4%
  • Osmotic effect on brain
  • Rapid rise in serum sodium concentration greater than 9 mEq/L in 24 hours osmotic demyelination syndrome
  • Reduction seen for ~ 2 hours
  • Target goal: sodium 145 – 155 mEq/L & osmolarity 320 mOsm/L
  • Corticosteroids
  • Glucocorticoids – penetrate BBB & decrease edema associated with mass
    lesions
  • Barbiturates
  • Barbiturate coma

Reduce refractory ICP – decreasing CMRO2 , scavenging free radicals,
preventing convulsions, & reducing hyperthermic response to ischemia

A
99
Q

Increased ICP Anesthetic Considerations:

Avoid sedatives
* Extremely sensitive to the CNS-depressant effects of medications
(opioid)

  • Consider serum concentrations of
    anticonvulsant medication
  • Continue corticosteroid therapy
  • Monitor for hyperglycemia & treat
  • Elevate head of bed 15 to 30 degrees during transport
  • Judicious fluid management
  • Avoid perioperative & postoperative hypertension
  • Monitor for venous air embolus
  • Induction slow & deliberate to avoid
    change in ICP & CPP
  • Slow & gentle emergence from anesthesia (avoid coughing & bucking)
A
100
Q

Temporary disruptions of brain function caused by
uncontrolled excessive neuronal activity

Temporary symptomatic seizures

  • Causes: multiple neurological or medical conditions
  • Acute electrolyte disorders
  • Hypoglycemia
  • Drugs (e.g., cocaine)
  • Eclampsia
  • Kidney failure
  • Hypertensive encephalopathy
  • Meningitis Epilepsy
  • Chronic condition of recurrent seizures - vary from brief and nearly undetectable symptoms to periods of vigorous shaking and convulsions
  • Not a single disease
  • Multiple underlying pathophysiological mechanisms that
    cause cerebral dysfunction and injury
A
101
Q

Epileptic Seizure Cause

  • Disruption of the normal balance between inhibitory and excitatory currents or transmission in one or more regions of the brain

Classification
* Focal
* Generalized

Aura
Postictal period
* time after the seizure, prior to the return of normal neurological function

Post-seizure depression

  • person remains in stupor for 1 minute to many minutes after the seizure attack is over and then often remains severely
    fatigued and asleep for hours thereafter
A
102
Q

Focal
Limited to a focal area of one cerebral hemisphere -
localized organic lesion or functional abnormality:

  • scar tissue in the brain that pulls
    on the adjacent neuronal tissue
  • tumor that compresses an area of the brain
  • destroyed area of brain tissue
  • congenitally deranged local circuitry

Lesions can promote extremely rapid
discharges in the local neurons

  • Classification
  • Simple partial seizures
  • no major change in consciousness
  • confined to a single area of the brain
  • Complex partial seizures
  • consciousness is impaired
  • repetitive movements
    (automatisms), such as chewing or lip smacking

Types:
* Automatisms
* Behavior arrest
* Hyperkinetic
* Autonomic
* Cognitive
* Emotional

A
103
Q

Generalized

Previously called grand mal seizures

Diffusely involve both hemispheres of the cerebral cortex

Abrupt loss of consciousness and extreme neuronal discharges in all areas of the brain

  • the cerebral cortex, the deeper parts of the cerebrum, and even the brain stem

Types
* Motor - (tonic-clonic, clonic, tonic, myoclonic, myoclonic-tonic-clonic, myoclonic-atonic, atonic, epileptic spasms)

  • Non-motor/absence - (typical, atypical, myoclonic, eyelid myoclonia)

Tonic-clonic seizures
* discharges transmitted all the way into the spinal cord sometimes cause generalized tonic seizures of the entire body, followed toward the end by alternating tonic and spasmodic muscle contractions

  • majority of generalized seizures are idiopathic
  • a hereditary predisposition
    Absence seizures (petit mal seizures)
  • usually begin in childhood or early adolescence
  • involve the thalamocortical brain activating system person often stares and has twitchlike contractions of
    muscles, usually in the head region, especially blinking of the eyes
  • characterized by 3 to 30 seconds of unconsciousness or diminished consciousness
A
104
Q

Seizure Treatment:

Antiepileptic drugs

  • Blockade of voltage-dependent sodium channels (e.g., carbamazepine
    and phenytoin)
  • Altered calcium currents (e.g., ethosuximide
  • Increase in GABA activity (e.g., phenobarbital and benzodiazepines)
  • Inhibition of receptors for glutamate, the most prevalent excitatory
    neurotransmitter (e.g., perampanel)
  • Multiple mechanisms of action (e.g., valproate and topiramate, which
    block voltage-dependent sodium channels and increase GABA levels
    in the brain

Surgical excision of the focus

  • EEG & MRI used to localize abnormal spiking waves originating in areas of organic brain disease that predispose to focal epileptic
    attacks
  • Resection of a pathologic region - a tumor, hamartoma, or scar tissue
  • Corpus callosotomy may help to prevent the generalization of partial
    seizures to the opposite hemisphere (rarely performed)
  • Hemispherectomy is sometimes needed for persistent catastrophic
    seizures (rarely performed)
A
105
Q

Anesthesia Considerations
Pre-operative

  • Focus on cause & type of seizure
  • Medication regimen & last dose
  • Last known episode

Perioperative

  • Avoid metabolic abnormalities
  • Aware of drug toxicities & adverse side effects
  • Maintain antiseizure medication
  • Avoid drugs with epileptogenic potential
  • Ketamine & methohexital

Post-operative

  • Observe for 4 – 6 hours after procedure

Perioperative Treatment

  • Maintain or establish patent airway
  • IV medications
  • Propofol 50-100mg
  • Phenytoin 500- 1000 mg slowly
  • Benzodiazepine
  • Diazepam 5-10 mg
  • Midazolam 1-5 mg
  • Correct metabolic abnormalities
A
106
Q

Intracranial tumors may be classified as primary (those arising from the brain and its coverings) or metastatic.

Primary brain tumors (gliomas) - originate from virtually any cell type within the central nervous system

Classification depends on histologic cell type

Supratentorial tumors - more common in adults
* headache, seizures, or new neurologic deficits

Infratentorial tumors - more common in children

  • obstructive hydrocephalus and ataxia

Treatment - surgical resection or debulking, chemotherapy, or radiation

As the tumor continues to grow, it will reach a certain size where these compensatory mechanisms will become exhausted

  • no further drainage of blood or CSF possible
  • equilibrium becomes disrupted
  • patient enters a decompensated state
  • intracranial pressure will begin to rise

Once volume compensation has reached exhaustion, the subsequent increasing ICP has a direct relationship
with a reduction in cerebral perfusion and an increased risk of herniation

A
107
Q

Gliomas Astrocytes
* most prevalent glial cells
* give rise to many infratentorial &
supratentorial tumors

Gliomas are primary central nervous system tumors that arise from glial progenitor cells.

The annual incidence of gliomas is reported
to be about 6 cases per 100,000 worldwide.

Type of gliomas:
* Astrocytoma
* Oligodendroglioma
* Glioblastoma

Different genomic signatures lead to
different clinical outcomes, thus necessitating different expectations and
treatment methods

Low-grade gliomas –well-differentiated, less
aggressive

The annual incidence of gliomas is reported
to be about 6 cases per 100,000 worldwide.

A
108
Q

Gliomas present with various symptoms, related to the location and
grade of the tumor.

Low-grade, slow-growing tumors

  • present with new-onset seizure or a more subtle progressive neurologic deficit

Higher-grade, faster-growing tumors

  • present with more acute neurologic symptoms combined with
    other symptoms

Common presenting symptoms
* Headache
* Seizure
* Cognitive dysfunction
* focal neurologic deficits

Headache is one of the most common non-specific symptoms in patients with brain tumors; however, it has a very low positive
predictive value

A
109
Q

Astrocytoma

Astrocytic tumors typically show diffusely infiltrating fibrillary glial cells with a microcytic background
and regional heterogeneity.

A
110
Q

Oligodendroglioma

  • Oligodendroglioma is a relatively slow-growing tumor with a predilection for the frontal lobe and is often associated with seizures.
  • Common histopathologic findings include a “fried egg” appearance with uniformly rounded nuclei and clear halos, “chicken-wire” patterned branching capillaries, and extensive
    calcifications.

*Generally associated with a favorable prognosis and a good response to chemotherapy.

A
111
Q

Glioblastoma

  • Glioblastoma is a highly malignant tumor that
    occurs most commonly in elderly patients, accounting for around 49% of primary malignant brain tumor.
  • The histologic hallmark of glioblastoma is necrosis and vascular proliferation, commonly seen together with marked pleomorphism and increased mitotic activity.
  • Characterized by rapid progression and has a
    median survival of 14–16 months after
    diagnosis
A
112
Q

Pituitary Tumor

10% intracranial neoplasms
Rarely metastatic

Hypersecretion of pituitary hormones

Symptoms
* Frontotemporal headache
* Bitemporal hemianopsia
* Excessive growth hormone
* Increased skeletal size
* Face, hands, & feet
* Intubation difficulty
* Coronary artery disease
* Hypertension
* Cardiomyopathy
* Hyperglycemia

A
113
Q

Cerebral Palsy:

Most prevalent cause of persistent motor impairment in children –
affecting 1-2 / 1000 births in developed countries

Cause
* Antenatal or perinatal injury to developing brain

Characterizations
* Nonprogressive abnormal movement & posture
* Spasticity
* Ataxia
* Dyskinesias
* Mild to moderate
* Isolated or involve cognitive impairment, speech disorders, &
seizures

Require multiple orthopedic surgeries:
* Soft tissue release
* Tendon lengthening for contractures
* Osteotomies for hip deformities
* Pinal fusion for scoliosis

A
114
Q

Cerebral Palsy:

Require psychosocial aspects as well as medical aspects of their
condition

Communications – cognitive delay, speech impairment, &
behavioral problems

  • Special accommodations
  • Parent or caretaker involvement
  • Speech impairment does not imply cognitive impairment

Seizure involvement
* Antiepileptic medications – type & frequency

  • Semiology
    Gastrointestinal (risk of aspiration)
  • GERD – common
  • Bulbar involvement - chronic aspiration & feeding
    difficulties – gastrostomy tube placement

Respiratory
* Infections
* Restrictive deficits – kyphoscoliosis – significant
pulmonary mobility impairment

Airway management
* Cervical kyphosis or dystonia

  • Lower minimum alveolar concentration
  • Prone to intraoperative hypothermia due to hypothalamic
    dysfunction
  • Correlation between cerebral palsy and latex allergy (exposure
    to multiple surgical procedures
A
115
Q

Spina Bifida:

Diverse group of congenital malformations of the spine & spinal cord

Pathophysiology
* Embryologically – failure of fusion of the neural tube

Open defects w/exposure of neural tissue

  • Myelomeningocele & myeloschisis
  • Associated w/ neurological deficits –repaired prenatally

Closed defects w/ skin covering

  • Meningocele, tethered cord, & split cord
  • Associated deficits vary – asymptomatic, sacral
    dimple, hemangioma, or tuff of hair

Neurological Abnormalities

  • Motor & sensory deficits below level of defect
  • Chiari II malformations, hydrocephalus,
    neurogenic bladder
A
116
Q

Spina Bifida:

Surgical procedures
* Orthopedic
* Correction of congenital or acquired limb deformities (club foot, hip dislocation)

  • Spinal fusion for scoliosis
  • Release of contractures
  • Tethered cord syndrome – cord release

Anesthesia implications

Neuraxial anesthesia

  • Increased dura puncture & failed block due to whether
    undergone corrective spinal surgery, anatomical abnormality
  • ligamentum flavum may be malformed or absent
  • Epidural space may be malformed or nonexistent
  • Cord tethering can result in low termination of spinal
    cord
  • If necessary thorough understanding of patient’s anatomy is required
  • MRI – allow examination of bony and ligamentous
    defect, termination of spinal cord, & presence of
    masses (lipoma & syrinx)
  • Avoid needle placement through surgical scars
  • Epidural placed above level of defect
  • Smaller boluses
  • Failed or incomplete block possible
A
117
Q

Depression & Manic-Depressive Psychosis

Cause
* Presumption manifestations are caused by:
* brain deficiency in dopamine, norepinephrine, & serotonin

  • Altered receptor activity
  • norepinephrine-secreting neurons - located in the brain stem
  • neurons send fibers upward to most parts of the brain limbic system, thalamus, and cerebral cortex
  • serotonin-producing neurons - located in the midline raphe nuclei of the lower pons and medulla
  • send fibers to many areas of the limbic system and to some other areas of the brain

Characterized

  • Sadness & pessimism
  • grief, unhappiness, despair, and misery
  • lose their appetite and sex drive
  • severe insomnia
A
118
Q
  1. Monoamine oxidase inhibitors
    * Block destruction of norepinephrine and serotonin once they are formed
    * Side effects
    * Hypotension
    * Agitation
    * Muscle spasm
    * Urinary retention
    * Paresthesia
    * Jaundice
    * Use opioids with caution
    * Avoid meperidine – hyperthermia, seizure, & coma
    * Enhanced sympathetic activity with ketamine, pancuronium, &
    epinephrine
  2. Tricyclic Antidepressants
    * Block reuptake of norepinephrine and serotonin by nerve endings
    * Increased anesthetic requirements – enhanced brain catecholamine
    activity
    * Potentiation of centrally acting anticholinergic agents (atropine &
    scopolamine)
    * Increased likelihood of confusion & delirium
    * Exaggerated response to indirect-acting vasopressors & sympathetic
    stimulation
    * Chronic therapy – depletion of cardiac catecholamines
    Treatment
    70% of depressive patients can be
    treated effectively with drugs that
    increase the excitatory effects of
    norepinephrine and serotonin at the
    nerve endings
  3. Selective Serotonin Reuptake Inhibitors
    * No anticholinergic activity
    * Generally, do not affect cardiac conduction
    * Serotonin Syndrome
    * Agitation, hypertension, hyperthermia, tremor, acidosis, &
    autonomic instability
  4. Norepinephrine Dopamine Reuptake Inhibitor
A
119
Q

Schizophrenia
Schizophrenia interferes with a person’s ability to think clearly, manage emotions, make decisions,
and relate to others.
Pathophysiology:
1. Multiple areas in the cerebral cortex prefrontal lobes
1. neural signals have become blocked
2. processing of the signals becomes dysfunctional b/c many synapses normally excited by the neurotransmitter glutamate
lose their responsiveness to this transmitter
2. Excessive excitement of a group of neurons that secrete dopamine in the behavioral centers of the
brain, including in the frontal lobes
3. Abnormal function of a crucial part of the brain’s limbic behavioral control system centered around the
hippocampus
4. Excessive dopamine
1. Excess dopamine is secreted by a group of dopamine-secreting neurons whose cell bodies lie in the ventral tegmentum
of the mesencephalon, medial and superior to the substantia nigra
2. Many drugs that are effective in treating schizophrenia, such as chlorpromazine, haloperidol, and thiothixene, all either
decrease secretion of dopamine at dopaminergic nerve endings or decrease the effect of dopamine on neurons

Characterizations
* Hearing voices and has delusions
* Intense fear
* Highly paranoid
* Develop incoherent speech
* Dissociation of ideas
* Abnormal sequences of thought
* Withdrawn & catatonic behavior
* Abnormal posture and even rigidity.
Schizophrenia: What It Is, Causes, Symptoms & Treatment
Risk Factors (No confirmed causes of schizophrenia)
* Environment
* Cerebral infections & autoimmune diseases

A
120
Q

Stroke Etiologies (5):

A
  • Large artery atherosclerosis
    (e.g., carotid stenosis)
  • Small vessel occlusion (e.g., lacunar stroke)
  • Cardioaortic embolic (e.g.,
    emboli from atrial fibrillation)
  • Other etiology (e.g., stroke due to hypercoagulable states or vasculopathies)
  • Undetermined etiology
121
Q

Stroke Diagnosis (3):

A
  • CT (non-contrast) - reliably
    distinguishes acute
    intracerebral hemorrhage from ischemia
  • Conventional angiography -useful for demonstrating
    arterial occlusion
  • Transcranial Doppler
    ultrasonography - indirect
    evidence of major vascular
    occlusion & real-time bedside monitoring in patients undergoing thrombolytic
    therapy
122
Q

Stroke Intervention Goal:

A

Goal: Restoring blood flow to ischemic penumbra & avoiding secondary cerebral damage

123
Q

Stroke considerations:

Anesthetic technique based on _________
basis - multiple prospective studies did not
demonstrate increased risk or poor outcome in
those who received general anesthesia over
monitored anesthesia care

A

Stroke considerations:

Anesthetic technique based on individualized
basis - multiple prospective studies did not
demonstrate increased risk or poor outcome in
those who received general anesthesia over
monitored anesthesia care

124
Q

Extradural Hemorrhage Symptoms:

*Progressive alteration in _____
* Increased ____
* Decreased ____

Treatment:
* Excellent prognosis with early ________ evacuation

A

Extradural Hemorrhage Symptoms:

*Progressive alteration in consciousness
* Increased ICP
* Decreased CPP

Treatment
* Excellent prognosis with early hematoma
evacuation

125
Q

Subdural Hemorrhage:

Etiology (2):

Signs & symptoms (5):

A

Subdural Hemorrhage:

Etiology:
* Trauma
* Anticoagulant therapy

Signs & symptoms:
* Drowsiness
* Obtundation
* Hemiparesis
* Hemianopsia
* Language disturbances

126
Q

Subdural Hemorrhage Treatment (4):

A

Treatment:
* Conservative medical stabilized condition
* Evacuation of hematoma
* Drained via Burr holes
* Craniotomy

127
Q

Arteriovenous
Malformation:

Congenital intracerebral networks – ______ flow directly into _____

*Lack ability to ________

A

Arteriovenous
Malformation:

Congenital intracerebral networks – arteries flow directly into veins

*Lack ability to autoregulate

128
Q

Arteriovenous
Malformation:

Signs & Symptoms (5):

Diagnosis (1):

A

Arteriovenous
Malformation
Signs & Symptoms:
* Headache
* New focal neurologic deficits
* Acute hemorrhage
* Seizures
* Hydrocephalus or macrocephaly

Diagnosis - MRI

129
Q

Severity of a subarachnoid hemorrhage (SAH) can be graded clinically with either the _____ & _____ or World Federation Surgeons Scale (Nagelhout; page 734)

A

Severity of a subarachnoid hemorrhage (SAH) can be graded clinically with either the Hunt & Hess or World Federation Surgeons Scale (Nagelhout; page 734)

130
Q

Despite maximal medical measures, ____% of patients who initially survive an SAH experience stroke or death secondary
to __________.

A
  • Despite maximal medical measures, 15% of patients who initially survive an SAH experience stroke or death secondary
    to vasospasm.
131
Q

Large brain tumor elevates the cerebrospinal fluid pressure by decreasing ______ of the cerebrospinal fluid back into
the blood.

A

Large brain tumor elevates the cerebrospinal fluid pressure by decreasing reabsorption of the cerebrospinal fluid back into
the blood.

132
Q

Hemorrhage or infection - number of red and/or white blood cells suddenly appear in the cerebrospinal fluid and can cause serious _____ of the small absorption channels through the ____ _________.

A

Hemorrhage or infection - number of red and/or white blood cells suddenly appear in the cerebrospinal fluid and can cause serious blockage of the small absorption channels through the arachnoidal villi.